ライフサイエンスコーパス: explantation

1 implantation, explantation, and 1 year after explantation).

2 and, in some cases, abundant at the time of explantation.

3 uggests a 24% probability of successful LVAD explantation.

4 AD placement and subsequently at the time of explantation.

5 ery systems, both improving the ease of lead explantation.

6 of severe vasculopathy at the time of heart explantation.

7 No device thrombosis was observed at explantation.

8 ical aberrations are leading indications for explantation.

9 jection of a selective inhibitor 2 hr before explantation.

10 and its mRNA after axotomy in vivo and after explantation.

11 latory factor-1 (IRF-1) were also induced by explantation.

12 e known consequent to an autopsy or surgical explantation.

13 of 28 consecutive patients within 4 hours of explantation.

14 vice replacement and 5 (9%) underwent device explantation.

15 and normoglycemia was maintained until graft explantation.

16 eatment in obtaining absence of HCC on liver explantation.

17 e membrane and development of melt requiring explantation.

18 ble improvement can be recognized before VAD explantation.

19 ing the final off-pump trial just before VAD explantation.

20 elationship with cardiac stability after VAD explantation.

21 ith the potential to remain stable after VAD explantation.

22 l integrity was maintained up to the time of explantation.

23 al mRNAs were detected as early as 9 h after explantation.

24 obtained in culture only with difficulty, by explantation.

25 and cell integration after in vitro retinal explantation.

26 rdial samples taken at LVAD implantation and explantation.

27 d 2.3-fold (P<0.01) and 1.2-fold (P<0.01) at explantation.

28 <0.05) between the times of implantation and explantation.

29 Levels returned to normal by 1 year after explantation.

30 cluding 3 repeat TPV implantations and 2 TPV explantations.

31 In the 11 cases requiring inlay explantations, 100% achieved a corrected distance visual

32 At explantation, 28 (36%) of 77 patients had HCC, 25 (32%)

33 Among patients with KPro explantation, 4 (36.4%) recovered better than baseline v

34 At liver explantation, 57 lesions were present in 18 patients: 19

35 levels in mouse trigeminal ganglia following explantation, a stimulus that results in HSV-1 reactivat

36 th a total of 38 lesions who underwent liver explantation after (90)Y radioembolization were studied.

37 r implantation and confirmation after sensor explantation allows separation of tissue mass transfer e

38 induction and seed development suggests that explantation and 2,4-D treatment initiates a course of e

39 iod between best cardiac improvement and VAD explantation and also during the final off-pump trial ju

40 adhesive activity recover quickly upon LVAD explantation and are not observed in patients with heart

41 ECD that warrants safe future combined pIOL explantation and cataract surgery.

42 Explantation and cutting of articular cartilage activate

43 ine in replicative capacity from the time of explantation and do so in a stochastic manner, with a ha

44 ed with a more proximal cuff, but 3 required explantation and open repair (7%).

45 an did famciclovir, rates of reactivation by explantation and UV exposure were the same.

46 patients underwent valve intervention (valve explantation and valve-in-valve procedure in 4 and 2 pat

47 of men in whom the device fails or requires explantation and we present the logical analysis for dev

48 12 recovery patients (at LVAD implantation, explantation, and 1 year after explantation).

49 istered ethanol (5 g/kg orally) 20 hr before explantation, and grafts were stored in UW cold storage

50 ality, hemodynamic improvement, freedom from explantation, and subjective and objective changes in ex

51 oup developed an infection necessitating DBS explantation, and was excluded from the assessment of th

52 Here we use in vivo and explantation assays to investigate tissue interactions a

53 Before explantation, at low flow for 15 minutes, ejection fract

54 One-year survival after LVAD explantation, available in INTERMACS for 21 (11%) patien

55 who underwent Boston type 1 keratoprosthesis explantation because of donor corneal melt at the Illino

56 Explantation because of postoperative subluxation or dis

57 His rate of explantation because of subluxation/dislocation was 0.76

58 various phenotypes whose identification upon explantation can be expensive and time-consuming.

59 All combination pIOL explantation/cataract surgeries resulted in the successf

60 urgical issues and outcomes of combined pIOL explantation/cataract surgery, and the prevention of cat

61 al strategies in performing combination pIOL explantation/cataract surgery.

62 ssues was analyzed by plaque assay, PCR, and explantation cocultivation in both immunocompetent and c

63 y more common in eyes that required a device explantation, compared to those that retained the device

64 PY mRNA also was increased following ganglia explantation, consistent with the increase in the number

65 Among 110 operated eyes, 11 eyes had KPro explantation, corresponding to a failure rate of 0.03/li

66 ng infected porcine corneas for 3 days in an explantation culture system for histologic evaluation of

67 At explantation, devices were sonicated and processed for q

68 owed relevant instability already before VAD explantation during the time period between best cardiac

69 Explantation/excision is likely to benefit recipients wi

70 Using embryo tissue explantation experiments, we find that the default fate

71 group survived to transplantation and 7% to explantation, findings comparable to those in the Late g

72 Independent predictors of device explantation for recovery were age <50 years (odds ratio

73 ollowed prospectively until transplantation, explantation for recovery, death, or for 1 year.

74 omyopathy (4.1%) had highest rates of device explantation for recovery.

75 Six subjects (9%) underwent LVAD explantation for recovery.

76 inally implanted device, transplantation, or explantation for ventricular recovery at 180 days and wa

77 re was a trend of increased mortality in the explantation group (11% versus 8%; P=0.06).

78 rtality risk was slightly higher in the lead explantation group, this difference was not statisticall

79 with implantable cardioverter-defibrillator explantation had an incidence rate of 19.3 (95% confiden

80 g lead abandonment, patients undergoing lead explantation had more in-hospital procedure-related comp

81 Similarly, patients undergoing lead explantation had slightly higher rates of in-hospital de

82 The management included IOL explantation in 7 of 9 cases, removal of fibrosis with p

83 r chamber modifications, and recommends PIOL explantation in cases of an increase in the crystalline

84 inhibition and pRb dephosphorylation on MEF explantation in culture.

85 clinical recovery is insufficient for device explantation in most patients with chronic heart failure

86 ly week 4 was chosen as the optimum time for explantation in the in vivo assay in that sufficient cal

87 ore 1:1 matching for ICD lead abandonment or explantation in the National Cardiovascular Data Registr

88 by retinal detachment in vivo and in retinal explantation in vitro.

89 sal tissue extirpation and cardiac primordia explantation indicate that cardiac left-right orientatio

90 al activity and relatively high frequency of explantation-induced reactivation in both immunocompeten

91 bility after ventricular assist device (VAD) explantation is a major goal.

92 Boston KPro explantation is a serious complication.

93 entricular assist device implantation and at explantation (mean duration, 185+/-156 days) and from 9

94 ent fracture, or corrosion up to the time of explantation (median, 119 days; first and third quartile

95 On the day of ECMO explantation (median, postoperative day 8), LV diameter

96 On explantation (n = 3276), 13% had microvascular invasion,

97 patients who had RAP > or = 15 mm Hg at LVAD explantation (n = 8) or who required an RV assist device

98 h debridement; however, no instances of mesh explantation occurred.

99 , with a survival rate to transplantation or explantation of 78%.

100 orylation of MAP kinase that usually follows explantation of explants.

101 V failures) experienced persistent hypotony, explantation of implant, or loss of light perception com

102 Explantation of infarcted neonatal and adult heart tissu

103 oteins were activated for up to 8 days after explantation of SCG in vitro.

104 l of immunosuppression, graft rejection, and explantation of the allograft after rejection has been e

105 Hyperglycemic blood glucose levels after explantation of the capsules confirmed the function of t

106 After explantation of the capsules, all mice became hyperglyce

107 ) were rapidly activated upon dissection and explantation of the cartilage.

108 e studied; 6 recovered sufficiently to allow explantation of the device compared with 9 who did not r

109 in all subjects except in one, who required explantation of the device without further complications

110 cardial function, sufficient enough to allow explantation of the device.

111 sistance can lead to myocardial recovery and explantation of the device.

112 er sufficient ventricular function to enable explantation of the device.

113 e of fewer severe complications that lead to explantation of the intraocular lens.

114 cardiomyocytes obtained from tissue taken at explantation of the LVAD in patients with clinical recov

115 t, 214 days) at the time of implantation and explantation of the LVAD.

116 Explantation of the LVADs without heart transplantation

117 Explantation of the pIOL occurred in 6.0% in the myopic

118 patients who recovered sufficiently to allow explantation of their LVAD can even achieve cardiac and

119 te from latency in vivo after DEX treatment, explantation of tonsil tissue from calves latently infec

120 ular route, and virus was not recovered upon explantation of trigeminal ganglia; (iv) although protei

121 observed in 76 to 82% of the eyes following explantation onto a permissive cell layer.

122 clinical outcomes after an intraocular lens explantation or exchange have also improved markedly wit

123 accompany the study of viral reactivation by explantation or peripheral viral shedding.

124 were either already infected at the time of explantation or soon after through cell-to-cell contact

125 btained through postmortem versus antemortem explantation or whether explantation was due to infectio

126 Large-scale studies to better address post-explantation outcomes are warranted.

127 ry were a better last-recorded vision before explantation (P = .0002) and better vision immediately a

128 actinin decreased by 1.6-fold at the time of explantation (P<0.05).

129 D implantation (pre-LVAD) and at the time of explantation (post-LVAD).

130 egral component failure that required device explantation prior to reaching elective replacement.

131 nts who retain the device, but a significant explantation rate due to infection or local complication

132 IGF-I mRNA was elevated at the time of LVAD explantation relative to donors, with 2 groups distingui

133 Histology of the thymic grafts at explantation revealed viable thymus with preservation of

134 Histology of the thymic autografts at explantation revealed viable thymus with preservation of

135 Microarray analysis of implantation and explantation samples of recovery patients further reveal

136 ever, some patients with LVEF >45 before VAD explantation show early recurrence of heart failure (HF)

137 Explantation studies provided evidence that myocardial c

138 ted the increase of STAT binding produced by explantation, suggesting the presence of a labile repres

139 (ii) After explantation the amounts of viral mRNAs increased wherea

140 led description of the methodology for heart explantation, tissue preparation, slicing with a vibrato

141 l samples were collected at implantation and explantation/transplantation.

142 After explantation, ventricular function declined in 2 PPCM pa

143 Final visual prognosis correlates with pre-explantation visual function (r = 0.68, P = .02).

144 Five-year freedom from reintervention and explantation was 76+/-4% and 92+/-3%, respectively.

145 em versus antemortem explantation or whether explantation was due to infection or upgrade.

146 MyoRing explantation was performed in 4 eyes (4%).

147 up, time and causes of device replacement or explantation were assessed and categorized.

148 ts with KPro retention, those requiring KPro explantation were associated with aniridia (P = .0038),

149 Patients with KPro explantation were identified and compared to those with

150 ose mRNA level was modified by the stress of explantation were isolated and sequenced.

151 A total of 53 lungs removed at autopsy or explantation were obtained for the study from 51 documen

152 If ICD generator explantations were performed instead of replacements in

153 No FAi explantations were required, nor were any participants l

154 Patients were aged 76.31 +/- 8.24 years at explantation, which was performed 81.5 +/- 32.2 months a

155 Eyes with AC IOL explantation with glued IOL implantation in a single set

156 ents are sufficient to allow ultimate device explantation without requiring transplantation; this rep